Search

EHA-Balkan Hematology Tutorial on Lymphoid Malignancies

“EHA and the Albanian Association of Hematology have jointly decided to postpone the first EHA-Balkan Hematology Tutorial in response to a request from the Albanian government to limit all international meetings.

Read more

EHA-SWG Scientific Meeting on Integrated Cell Tracking in Oncohematology: Diagnosis, Targeted Therapy and Residual Disease

Dates: November 10-12, 2022
Location: Bordeaux, France
Format: Hybrid
Chair: MC Béné

Registration has closed

This was the third time EHA is collaborating with the EHA Specialized Working Group on Diagnosis in hematological diseases, to bring you the latest in laboratory hematology.…

Read more

EHA-KCS Hematology Tutorial on Lymphoma and Multiple Myeloma

Dates: March 14-16, 2019
Location: Almaty, Kazakhstan
Chairs: G Gaidano, D Kaidarova
Co-chairs: S Gabbasova, B Afanasyev 

This meeting will be held in English and offer a simultaneous translation to Russian.

Read more

Dutch scientists propose algorithm to keep drugs affordable and accessible

May 8, 2018, The Hague - An important contribution to the debate about the affordability and accessibility of innovative medicines appeared in Nature Reviews, proposing the adoption of a novel model of price setting with examples of implementation.

Read more

Meeting program

Thursday, October 12*All times are in EET.

Read more

EHA-BMSH Balkan Hematology Tutorial

EHA is joining the Bulgarian Medical Society of Hematology (BMSH) to organize the EHA-BMSH Balkan Hematology Tutorial on Myeloproliferative disorders.

Read more

EU Calls for Proposal 2022

Introduction
Spurred by COVID-19 and rising challenges to the financial sustainability of Europe’s health systems, a flurry of new EU policies and programs in health has sprung up since last year.

Read more

Ibrutinib improves survival in CLL and SLL patients: Results From the RESONATE Study.

 

Patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL) who experience short response duration or adverse cytogenetics have poor outcomes.

Read more